Based on all of the above, our work aims to investigate the targeting potential of ImI-modified nanomedicines for the treatment of α7-nAChR-overexpressed NSCLC in vitro and in vivo. The gene discussed is CHRNA7; the disease is non-small cell lung carcinoma.